Trial Profile
A Retrospective study to evaluate Subfoveal choroidal thickness as a predictor of response to Bevacizumab or Ranibizumab treatment in patients with polypoidal choroidal vasculopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Apr 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Therapeutic Use
- 18 Apr 2017 New trial record